Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | PRNP | P04156 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28941187 | 0.89 | ALDH1A1 (0.57) | ALDH1A1CYP1A2CYP2C19KDM4ETSHR | |
| SCHEMBL20564150 | 0.89 | ALDH1A1 (0.64) | ALDH1A1CYP1A2CYP2C19KDM4ETSHR | |
| SCHEMBL20563891 | 0.89 | ALDH1A1 (0.64) | ALDH1A1CYP1A2CYP2C19KDM4ETSHR | |
| SCHEMBL1609857 | 0.87 | ALDH1A1 (0.53) | ALDH1A1CYP1A2CYP2C19KDM4EMAPT | |
| SCHEMBL6818074 | 0.86 | ALDH1A1 (0.70) | ALDH1A1CYP1A2CYP2C19KDM4ETSHR | |
| SCHEMBL32690685 | 0.82 | ALDH1A1 (0.64) | ALDH1A1CYP1A2CYP2C19KDM4ETDP1 | |
| SCHEMBL32690661 | 0.82 | ALDH1A1 (0.64) | ALDH1A1CYP1A2CYP2C19KDM4ETDP1 | |
| SCHEMBL177349 | 0.82 | ALDH1A1 (0.58) | ALDH1A1CYP1A2CYP2C19KDM4ETDP1 | |
| SCHEMBL11784162 | 0.82 | ALDH1A1 (0.58) | ALDH1A1CYP1A2CYP2C19KDM4EMAPT | |
| SCHEMBL3643556 | 0.82 | KDM4E (0.62) | ALDH1A1CYP1A2CYP2C19KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1079821-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2001-08-29 | — | — | EP | claimed |
| EP-1079821-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-07 | — | — | EP | claimed |
| WO-1999059570-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-25 | — | — | WO | claimed |
| EP-1320370-A4 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORP (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1320370-A1 | METHOD OF TREATMENT | SmithKline Beecham Corporation (US) | 2003-06-25 | — | — | EP | disclosed |
| US-20030044399-A1 | Method of treatment | SMITHKLINE BEECHAM CORPORATION | 2003-03-06 | — | — | US | disclosed |
| EP-1093367-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2003-03-05 | — | — | EP | disclosed |
| WO-2002017924-A1 | METHOD OF TREATMENT | SMITHKLINE BEECHAM CORPORATION (GB) | 2002-03-07 | — | — | WO | disclosed |
| EP-1079821-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2001-08-29 | — | — | EP | disclosed |
| EP-1093367-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-04-25 | — | — | EP | disclosed |
| EP-1079821-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999066925-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999059570-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030044399-A1 | Method of treatment | DNPEP, PEPD, ANPEP | ALDH1A1 1483/4885CYP1A2 701/4885CYP2C19 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.